Susan L. Hogan, PhD, MPH; Ronald J. Falk, MD; Patrick H. Nachman, MD; J. Charles Jennette, MD
Potential Financial Conflicts of Interest: None disclosed.
Hogan S., Falk R., Nachman P., Jennette J.; Various Forms of Life in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Ann Intern Med. 2006;144:377-378. doi: 10.7326/0003-4819-144-5-200603070-00019
Download citation file:
Published: Ann Intern Med. 2006;144(5):377-378.
TO THE EDITOR:
We must disagree with some of the concepts described by Hoffman and Langford (1) in their editorial written in response to our evaluation of relapse and treatment resistance in antineutrophil cytoplasmic antibody (ANCA)–associated small-vessel vasculitis (2). The editorial primarily addressed 1) the clinical value of our results given that our cohort was not homogeneous and included patients with small-vessel vasculitis manifesting as Wegener granulomatosis, microscopic polyangiitis, and renal-limited pauci-immune necrotizing glomerulonephritis; 2) the usefulness of our requirement for ANCA seropositivity as the primary classification criterion; and 3) the risks and benefits of prolonged therapy. The authors disagreed with our suggestion that physicians should carefully weigh the risk for therapeutic complications associated with prolonged prophylactic therapy against the risk for relapse with or without therapy. This final point is one that we anticipated might generate discussion as our study challenges the current rote therapy used in this disease.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only